During the past decade, Dana-Farber/Brigham and Women's Cancer Center at Milford Regional conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 25 clinical trials were completed, i.e. on average, 67.6% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 16 clinical trials were completed. i.e. 94.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Dana-Farber/Brigham and Women's Cancer Center at Milford Regional" #1 sponsor was "Dana-Farber Cancer Institute" with 16 trials, followed by "Alliance for Clinical Trials in Oncology" with 12 trials sponsored, "National Cancer Institute (NCI)" with 12 trials sponsored, "SWOG Cancer Research Network" with 5 trials sponsored and "ECOG-ACRIN Cancer Research Group" with 5 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dana-Farber/Brigham and Women's Cancer Center at Milford Regional" #1 collaborator was "National Cancer Institute (NCI)" with 26 trials as a collaborator, "NRG Oncology" with 5 trials as a collaborator, "Canadian Cancer Trials Group" with 3 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator and "Bristol-Myers Squibb" with 2 trials as a collaborator. Other collaborators include 23 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "Dana-Farber/Brigham and Women's Cancer Center at Milford Regional" are "Breast Cancer" (11 trials), "Invasive Breast Carcinoma" (4 trials), "Prostate Cancer" (4 trials), "Recurrent Squamous Cell Lung Carcinoma" (4 trials) and "Colorectal Cancer" (3 trials). Many other conditions were trialed in "Dana-Farber/Brigham and Women's Cancer Center at Milford Regional" in a lesser frequency.

Most popular intervention types in "Dana-Farber/Brigham and Women's Cancer Center at Milford Regional" are "Drug" (45 trials), "Other" (31 trials), "Biological" (13 trials), "Radiation" (11 trials) and "Procedure" (6 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (16 trials), "Paclitaxel" (11 trials), "Quality-of-Life Assessment" (9 trials), "Carboplatin" (8 trials) and "Nivolumab" (6 trials). Other intervention names were less common.

The vast majority of trials in "Dana-Farber/Brigham and Women's Cancer Center at Milford Regional" are 44 trials for "All" genders, 7 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "Dana-Farber/Brigham and Women's Cancer Center at Milford Regional". undefined are not yet recruiting, 17 are recruiting, 25 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Dana-Farber/Brigham and Women's Cancer Center at Milford Regional, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Dana-Farber/Brigham and Women's Cancer Center at Milford Regional, 2 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 30 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 6 trials that are defined as “Not Applicable".